# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Five independent members of MAIA's Board of Directors purchased shares in the offeringMAIA Biotechnology, Inc., (NYSE:MAIA)...
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...
Dr. Smith has participated in every MAIA funding roundMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company...
Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell l...
THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications...
Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent i...